Bill > HB1734

This bill establishes a framework for creating experimental treatment centers in New Hampshire that can provide access to investigational drugs, biologics, or devices that have completed initial clinical trials but are not yet FDA-approved. The bill creates a new legal pathway for patients with serious medical conditions to access cutting-edge treatments through a carefully regulated process. Under the bill, patients must receive a recommendation from their treating physician, provide written informed consent understanding the potential risks and that insurance may not cover the treatment, and meet specific eligibility criteria. Experimental treatment centers must obtain authorization from the Department of Health and Human Services, pay initial and annual fees, establish a scientific review board with at least three members, and maintain rigorous documentation and safety protocols. The centers must also allocate 2% of their annual net profits to support access to experimental treatments for qualifying New Hampshire residents, either by providing free treatments or contributing to specific state health funds. The bill aims to attract clinical trials and innovative medical research to the state while providing safeguards to protect patient safety, with provisions that prevent medical licensing boards from taking action against physicians who recommend these experimental treatments. The experimental treatment centers will be legally distinct from traditional medical facilities and will have flexibility in establishing payment structures and manufacturing protocols. The act is set to take effect on January 1, 2027, and is estimated to have a minimal fiscal impact of less than $10,000 annually.

Health and Social Services

https://gc.nh.gov/bill_Status/billinfo.aspx?id=2009&inflect=2